退市公司R普利1，再“吃”罚单

Core Viewpoint - R Puli 1 (Puli Pharmaceutical Co., Ltd.) is facing significant regulatory scrutiny and financial challenges, including a recent fine for failing to disclose its 2024 annual report on time, which adds to its existing issues related to previous financial misconduct [1][2][3]. Group 1: Regulatory Issues - On November 28, R Puli 1 received an administrative penalty notice from the Hainan Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for not disclosing its 2024 annual report within the legal timeframe, resulting in a fine of 500,000 yuan [1]. - The company had previously faced penalties for financial fraud, including a total of 1.029 billion yuan in inflated revenue and 669 million yuan in inflated profits over two years, leading to a fine of 10 million yuan and market bans for key executives [3]. Group 2: Financial Challenges - As of the end of Q3 2024, R Puli 1 reported cash reserves of only 331 million yuan, while its short-term liabilities due within a year amount to 541 million yuan, indicating a concerning short-term solvency issue [4]. - The company is under significant pressure from both the risk of delisting and a looming debt crisis, exacerbated by the recent regulatory penalties [4].